Reconciling competition and IP law: the case of patented pharmaceuticals and dominance abuse

C. Fonteijn, I. Akker and W. Sauter, here. 

Concurrences conference on innovation economics 2018: two interviews

On excessive pricing, here; on Fintech ❤️ (the GDPR making data “more open” and “less proprietary”? An interesting view indeed!),  here.

Bundeskartellamt will Lufthansa-Preise prüfen

FAZ, hier.

Panel: Pharmaceutical Drugs Prices

H. First summarizes, Video here.
"The invisible hand got stuck in the pocket"

EU competition law in innovation and digital markets: fairness and the consumer welfare perspective

J. Laitenberger,  here.

EU tests limits of drug pricing freedom in landmark probe

Reuters, here.

Apple uses Supreme Court decision to attack Qualcomm

FT, here and here.
Complaint here.

Decision: Unfair pricing in respect of the supply of phenytoin sodium capsules in the UK

CMA, Case CE/9742-13, here. 

CAT rejects Flynn Pharma's request for interim relief to suspend CMA's order to lower prices for epilepsy treatment

Judgment here. 

New approach needed to tackle rising drug prices

OECD, here. 

Actavis Targeted by U.K. for Raising Drug Price by 12,000%

Bloomberg, here. 

Pharmaceutical Antitrust: What the Trump Administration Can Do

M. Carrier, here. 

CMA fines Pfizer and Flynn £90 million for drug price hike to NHS

CMA, here.

Protecting consumers from exploitation

M. Vestager, here. Video here. 

State Commercial Court of Moscow District confirmed legitimacy of FAS refusal to register excessive prices for medicinal drugs

FAS, here. 

Investigation into suspected breaches of competition law in the pharmaceutical sector.

CMA, here.

Abuse of dominance by firms charging excessive or unfair prices: an assessment

F. Jenny, here.